- Home
- TECK vs BIIB Comparison
TECK vs BIIB Comparison
Compare TECK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECK
- BIIB
- Stock Information
- Founded
- TECK 1913
- BIIB 1978
- Country
- TECK Canada
- BIIB United States
- Employees
- TECK N/A
- BIIB N/A
- Industry
- TECK
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TECK
- BIIB Health Care
- Exchange
- TECK Nasdaq
- BIIB Nasdaq
- Market Cap
- TECK 24.9B
- BIIB 25.1B
- IPO Year
- TECK N/A
- BIIB 1991
- Fundamental
- Price
- TECK $41.18
- BIIB $149.02
- Analyst Decision
- TECK Buy
- BIIB Buy
- Analyst Count
- TECK 7
- BIIB 26
- Target Price
- TECK $64.86
- BIIB $248.00
- AVG Volume (30 Days)
- TECK 2.4M
- BIIB 1.6M
- Earning Date
- TECK 02-19-2025
- BIIB 02-11-2025
- Dividend Yield
- TECK 1.78%
- BIIB N/A
- EPS Growth
- TECK N/A
- BIIB 10.05
- EPS
- TECK 0.69
- BIIB 11.06
- Revenue
- TECK $12,329,841,958.00
- BIIB $9,607,500,000.00
- Revenue This Year
- TECK N/A
- BIIB N/A
- Revenue Next Year
- TECK N/A
- BIIB N/A
- P/E Ratio
- TECK $58.17
- BIIB $13.47
- Revenue Growth
- TECK 114.29
- BIIB N/A
- 52 Week Low
- TECK $36.50
- BIIB $145.07
- 52 Week High
- TECK $55.13
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- TECK 33.94
- BIIB 32.44
- Support Level
- TECK $39.75
- BIIB $145.07
- Resistance Level
- TECK $47.86
- BIIB $149.92
- Average True Range (ATR)
- TECK 1.05
- BIIB 3.81
- MACD
- TECK -0.34
- BIIB 0.05
- Stochastic Oscillator
- TECK 17.63
- BIIB 22.51
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.